These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 37308276)
1. SARS-CoV-2 cross-sectional seroprevalence study among public school staff in Metro Vancouver after the first Omicron wave in British Columbia, Canada. Watts AW; Mâsse LC; Goldfarb DM; Irvine MA; Hutchison SM; Muttucomaroe L; Poon B; Barakauskas VE; O'Reilly C; Bosman E; Reicherz F; Coombs D; Pitblado M; O'Brien SF; Lavoie PM BMJ Open; 2023 Jun; 13(6):e071228. PubMed ID: 37308276 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 seroprevalence among Vancouver public school staff in British Columbia, Canada: a cross-sectional study. Goldfarb DM; Mâsse LC; Watts AW; Hutchison SM; Muttucomaroe L; Bosman ES; Barakauskas VE; Choi A; Dhillon N; Irvine MA; Reicherz F; O'Reilly C; Sediqi S; Xu RY; Razzaghian HR; Sadarangani M; Coombs D; O'Brien SF; Lavoie PM BMJ Open; 2022 Apr; 12(4):e057846. PubMed ID: 35383082 [TBL] [Abstract][Full Text] [Related]
3. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada. Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845 [TBL] [Abstract][Full Text] [Related]
4. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. Skowronski DM; Kaweski SE; Irvine MA; Kim S; Chuang ESY; Sabaiduc S; Fraser M; Reyes RC; Henry B; Levett PN; Petric M; Krajden M; Sekirov I CMAJ; 2022 Dec; 194(47):E1599-E1609. PubMed ID: 36507788 [TBL] [Abstract][Full Text] [Related]
5. Seropositivity of SARS-CoV-2 in an unvaccinated cohort in British Columbia, Canada: a cross-sectional survey with dried blood spot samples. Racey CS; Booth A; Albert A; Smith LW; Krajden M; Murray MCM; Côté HCF; Gottschlich A; Goldfarb DM; Sadarangani M; Galea LAM; Kaida A; Brotto LA; Ogilvie GS BMJ Open; 2022 Aug; 12(8):e062567. PubMed ID: 36038173 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States. Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144 [TBL] [Abstract][Full Text] [Related]
7. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era. Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385 [TBL] [Abstract][Full Text] [Related]
8. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard. Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095 [TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study. Lewin A; De Serres G; Grégoire Y; Perreault J; Drouin M; Fournier MJ; Tremblay T; Beaudoin J; Boivin A; Goyette G; Finzi A; Bazin R; Germain M; Delage G; Renaud C Can J Public Health; 2022 Jun; 113(3):385-393. PubMed ID: 35380364 [TBL] [Abstract][Full Text] [Related]
10. Measuring the clustering effect of the SARS-CoV-2 transmission in a school population: a cross-sectional study in a high incidence region. Severo M; Meireles P; Ribeiro AI; Morais V; Barros H Sci Rep; 2023 Sep; 13(1):16300. PubMed ID: 37770455 [TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of anti-SARS-CoV-2 IgG Antibodies in the Staff of a Public School System in the Midwestern United States. Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M medRxiv; 2020 Oct; ():. PubMed ID: 33140066 [TBL] [Abstract][Full Text] [Related]
12. National cross-sectional survey of 1.14 million NHS staff SARS-CoV-2 serology tests: a comparison of NHS staff with regional community seroconversion rates. Coltart CEM; Wells D; Sutherland E; Fowler A BMJ Open; 2021 Jul; 11(7):e049703. PubMed ID: 34257096 [TBL] [Abstract][Full Text] [Related]
14. Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020-February 2022. Duong S; Burtniak J; Gretchen A; Mai A; Klassen P; Wei Y; Loeppky C; Shaw SY; Bullard J; Van Caeseele P; Stein DR BMC Public Health; 2023 Dec; 23(1):2420. PubMed ID: 38053033 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 seroprevalence and mental health of school staff: a cross-sectional study of schools from four areas of Montreal, Quebec in 2021. Charland K; Pannunzio M; Greenspan-Ardman E; Saucier A; Pierce L; Hamelin ME; Barbosa Da Torre M; Carbonneau J; Tuong Nguyen C; De Serres G; Papenburg J; Boivin G; Quach C; Zinszer K BMJ Open; 2024 Aug; 14(8):e081838. PubMed ID: 39182934 [TBL] [Abstract][Full Text] [Related]
16. Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study. Ladoire S; Rederstorff E; Goussot V; Parnalland S; Briot N; Ballot E; Truntzer C; Ayati S; Bengrine-Lefevre L; Bremaud N; Coudert B; Desmoulins I; Favier L; Fraisse C; Fumet JD; Hennequin A; Hervieu A; Ilie S; Kaderbhai C; Lagrange A; Martin N; Mazilu I; Mayeur D; Palmier R; Simonet-Lamm AL; Vincent J; Zanetta S; Arnould L; Coutant C; Bertaut A; Ghiringhelli F Eur J Cancer; 2022 Apr; 165():13-24. PubMed ID: 35189537 [TBL] [Abstract][Full Text] [Related]
17. Heterogeneous evolution of SARS-CoV-2 seroprevalence in school-age children: Results from the school-based cohort study Ciao Corona in November-December 2021 in the canton of Zurich. Haile SR; Raineri A; Rueegg S; Radtke T; Ulyte A; Puhan MA; Kriemler S Swiss Med Wkly; 2023 Jan; 153():40035. PubMed ID: 36787493 [TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India. Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA Front Public Health; 2022; 10():967447. PubMed ID: 36276377 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study. Ng OT; Marimuthu K; Koh V; Pang J; Linn KZ; Sun J; De Wang L; Chia WN; Tiu C; Chan M; Ling LM; Vasoo S; Abdad MY; Chia PY; Lee TH; Lin RJ; Sadarangani SP; Chen MI; Said Z; Kurupatham L; Pung R; Wang LF; Cook AR; Leo YS; Lee VJ Lancet Infect Dis; 2021 Mar; 21(3):333-343. PubMed ID: 33152271 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 among workers of a comprehensive cancer centre between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain. Peremiquel-Trillas P; Saura-Lázaro A; Benavente-Moreno Y; Casabonne D; Loureiro E; Cabrera S; Duran A; Garrote L; Brao I; Trelis J; Galán M; Soler F; Julià J; Cortasa D; Domínguez MÁ; Albasanz-Puig A; Gudiol C; Ramírez-Tarruella D; Muniesa J; Rivas JP; Muñoz-Montplet C; Sedano A; Plans À; Calvo-Cerrada B; Calle C; Clopés A; Carnicer-Pont D; Alemany L; Fernández E BMJ Open; 2022 Apr; 12(4):e056637. PubMed ID: 35450905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]